296856.fig.003a
(a)
296856.fig.003b
(b)
296856.fig.003c
(c)
Figure 3: Frequency of clinical scores of asthma at day zero (D0) and day 30 to day 90 (D30–D90) after treatment with placebo (Plac) of Albendazole (Alb) and placebo of Praziquantel (PZQ) (Group 1; (a)); and frequency of clinical scores of asthma at day zero (D0) and day 30 to 90 (D30–D90) after treatment with Albendazole and Praziquantel (Group 2; (b)). Data were represented as m e a n ± S D . (c) shows the frequency of clinical scores of asthma (0, 1, 2, 3, 4) at day zero (D0) and at 6 months, 12 months and 18 months after treatment with Praziquantel (Figure 3(c)). Patients were evaluated monthly from day 30 to day 90 (D30–D90). After 90 days of enrollment, both placebo and treatment groups were treated with Albendazole and Praziquantel. From there clinical scores of asthma were assessed each 6 months for a total period of 18 months. *D0 versus 6 m or D0 versus 12 m, 𝑃 < 0 . 0 5 ; Fisher’s exact test.